Alpha-1 Antitrypsin Deficiency
Conditions
Brief summary
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
Interventions
DRUGWVE-006
RNA editing oligonucleotide
Sponsors
Wave Life Sciences Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Healthy as determined by the Investigator, based on a medical evaluation, or has mild to moderate AATD-induced lung disease (FEV1 ≥50%) and/or stable mild AATD-induced liver disease (≤F2 (≤10 kPa) on FibroScan. * Genetic testing confirming Pi\*ZZ. * Participant has been a non-smoker for at least 1 year prior to screening.
Exclusion criteria
* • Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc). * Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections. * Any ongoing or recent infections. * Any recent or planned vaccinations during the study. * Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week. * Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits. * Any recent or planned major surgery during the study. * Participant has any medical condition or social circumstance that, in the opinion of the Investigator, would make the participant unsuitable for participation in the study or for dosing on Day 1, or could interfere with the assessments of safety, pharmacodynamics, or pharmacokinetics, or completion of the study. * Participant currently on AAT augmentation therapy, planned to be on augmentation therapy anytime during the study, or has been on augmentation therapy within 30 days prior to Screening Visit. * Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study. * Participant has received an investigational agent within 3 months of the Screening Visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of participants with adverse events | Up to 36 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| Single Ascending Dose - Change from baseline in levels of serum M-AAT protein. | Up to 12 Weeks |
| Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein | Up to 24 Weeks |
| Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) | Up to 12 Weeks |
| Single Ascending Dose - Maximum concentration of WVE-006 in plasma | Up to 12 Weeks |
| Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) | Up to 24 Weeks |
| Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax) | Up to 24 Weeks |
Countries
Australia, Canada, Finland, Germany, New Zealand, United Kingdom
Contacts
STUDY_DIRECTORMedical Director, MD
Wave Life Sciences
Outcome results
None listed